Protein C pathway in sepsis

Annals of Medicine

Volumn 34, Issue 7-8, 2002, Pages 598-605

  Esmon, Charles T ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

Anticoagulant; Complement; Endothelium; Endotoxin; EPCR; Protein C; Sepsis; Thrombin; Thrombomodulin; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8A; ENDOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; PROTEIN S; THROMBIN; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA; VITRONECTIN;

ANTIINFLAMMATORY ACTIVITY; BLOOD CLOT LYSIS; BLOOD CLOTTING; CLINICAL TRIAL; CONTINUOUS INFUSION; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; GENE TRANSLOCATION; HUMAN; IN VITRO STUDY; MICROVASCULARIZATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; THROMBOCYTE MEMBRANE; THROMBOSIS;

EID: 0036957150     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.1080/078538902321117823     Document Type: Review

References (53)

1. Esmon CT. Protein C, protein S, and thrombomodulin. In: Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th edn. Philadelphia: Lippincott Williams & Wilkins; 2001: 335-53.
2. Stearns-Kurosawa DJ, Kurosawa S, Mollica JS, Ferrell GL, Esmon CT. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. Proc Natl Acad Sci USA 1996; 93: 10212-6.
3. Laszik Z, Mitro A, Taylor FB, Jr., Ferrell G, Esmon CT. Human protein C receptor is present primarily on endothelium of large blood vessels: Implications for the control of the protein C pathway. Circulation 1997; 96: 3633-40.
4. Liaw PCY, Neuenschwander PF, Smirnov MD, Esmon CT. Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. J Biol Chem 2000; 275: 5447-52.
5. Shu F, Kobayashi H, Fukudome K, Tsuneyoshi N, Kimoto M, Terao T. Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner. FEBS Lett 2000; 477: 208-12.
6. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-2.
7. Grey S, Han H, Salem HH, Hancock WW. Selective effects of protein C on activation of human monocytes by lipopolysaccharide, interferon-gamma, or PMA: Modulation of effects on CD11b and CD14 but not CD25 or CD54 induction. Transplant Proc 1993; 25: 2913-4.
8. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199-203.
9. 2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin, and plasmin. J Biol Chem 1991; 266: 17606-12.
10. Gruber A, Griffin JH. Direct detection of activated protein C in blood from human subjects. Blood 1992; 79: 2340-8.
11. Stenflo J. The biochemistry of protein C. In: Bertina RM, ed. Protein C and related proteins. London: Churchill-Livingstone; 1988: 21-54.
12. Regan LM, Mollica JS, Rezaie AR, Esmon CT. The interaction between the endothelial cell protein C receptor and protein C is dictated by the Gla domain of protein C. J Biol Chem 1997; 272: 26279-84.
13. Rezaie AR, Cooper ST, Church FC, Esmon CT. Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex. J Biol Chem 1995; 270: 25336-9.
14. Bourin MC, Lindahl U. Glycosaminoglycans and the regulation of blood coagulation. Biochem J 1993; 289: 313-30.
15. Rezaie AR. Vitronectin functions as a cofactor for rapid inhibition of activated protein C by plasminogen activator inhibitor-1. Implications for the mechanism of profibrinolytic action of activated protein C. J Biol Chem 2001; 276: 15567-70.
16. Bajzar L, Morser J, Nesheim M. TAFI, or Plasma Procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
17. Campbell WD, Lazoura E, Okada N, Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002; 46: 131-4.
18. Campbell W, Okada N, Okada H. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Immunol Rev 2001; 180: 162-7.
19. Ikeguchi H, Maruyama S, Morita Y, Fujita Y, Kato T, Natori Y, et al. Effects of human soluble thrombomodulin on experimental glomerulonephritis. Kidney Int 2002; 61: 490-501.
20. Kurosawa S, Esmon CT, Stearns-Kurosawa DJ. The soluble endothelial protein C receptor binds to activated neutrophils: Involvement of proteinase-3 and CDIIb/CD18. J Immunol 2000; 165: 4697-703.
21. Taylor FB, Jr., Stearns-Kurosawa DJ, Kurosawa S, Ferrell G, Chang AC, Laszik Z, et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood 2000; 95: 1680-6.
22. Oganesyan V, Oganesyan N, Terzyan S, Qu D, Dauter Z, Esmon NL, et al. The crystal structure of the endothelial protein C receptor and a bound phospholipid. J Biol Chem 2002; 277: 24851-4.
23. Hong S, Scherer DC, Singh N, Mendiratta SK, Serizawa I, Koezuka Y, et al. Lipid antigen presentation in the immune system learned from CD1d knockout mice. Immunol Rev 1999; 169: 31-44.
24. Moody DB, Ulrichs T, Mühlecker W, Young DC, Gurcha SS, Grant E, et al. CD1c-mediated T-cell recognition of isoprenoid glycolipids in Mycobacterium tuberculosis infection. Nature 2000; 404: 884-8.
25. Esmon CT. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 1989; 264: 4743-6.
26. Esmon CT, Owen WG. Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C. Proc Natl Acad Sci USA 1981; 78: 2249-52.
27. Dreyfus M, Magny JF, Bridey F, Schwarz HP, Planche C, Dehan M, et al. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991; 325: 1565-8.
28. Fukudome K, Esmon CT. Identification, cloning and regulation of a novel endothelial cell protein C/activated protein C receptor. J Biol Chem 1994; 269: 26486-91.
29. Conway EM, Rosenberg RD. Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells. Mol Cell Biol 1988; 8: 5588-92.
30. Glaser CB, Morser J, Clarke JH, Blasko E, McLean K, Kuhn I, et al. Oxidation of a specific methionine in thrombomodulin by activated neutrophil products blocks cofactor activity. J Clin Invest 1992; 90: 2565-73.
31. Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76: 2024-9.
32. Hancock WW, Grey ST, Han L, Akalin E, Orthner C, Sayegh MH, et al. Binding of activated protein C to a specific receptor on human mononuclear phagocytes inhibits intracellular calcium signaling and monocyte-dependent proliferative responses. Transplantation 1995; 60: 1525-32.
33. Yuksel M, Uchiba M, Okajima K, Okabe H. Activated protein C inhibits LPS-induced production of TNF-alpha by monocytes through inhibition of activation of NF-kappaB and MAPK pathways. Thromb Haemost 2001; (Suppl. July): P508.
34. Taoka Y, Okajima K, Uchiba M, Murakami K, Harada N, Johno M, et al. Activated protein C reduces the severity of compression-induced spinal cord injury in rats by inhibiting activation of leukocytes. J Neurosci 1998; 18: 1393-8.
35. White B, Schmidt M, Murphy C, Livingstone W, O'Toole D, Lawler M, et al. Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line. Br J Haematol 2000; 110: 130-4.
36. Coughlin SR. Thrombin receptor function and cardiovascular disease. Trends Cardiovasc Med 1994; 4: 77-83.
37. Comp PC, Jacocks RM, Ferrell GL, Esmon CT. Activation of protein C in vivo. J Clin Invest 1982; 70: 127-34.
38. Beller-Todd BK, Archer LT, Hinshaw LB. Recovery from endotoxin shock after extracorporeal perfusion without anticoagulation. Circ Shock 1997; 6: 261-9.
39. Taylor FB, Jr., Chang A, Hinshaw LB, Esmon CT, Archer LT, Beller BK. A model for thrombin protection against endotoxin. Thromb Res 1984; 36: 177-85.
40. Taylor FB, Jr., Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE. Protein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon. J Clin Invest 1987; 79: 918-25.
41. Taylor FB, Jr., Esmon CT. Treatment of dysfunctional vascular endothelium using activated protein C. U.S. Patent No. 5, 009, 889; 1991.
42. Taylor F, Chang A, Ferrell G, Mather T, Catlett R, Blick K, et al. C46-binding protein exacerbates the host response to Escherichia coli. Blood 1991; 78: 357-63.
43. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 1997; 272: L197-202.
44. Fisher CJ, Yan SB. Protein C levels as a prognostic indicator of outcome in sepsis and related diseases. Crit Care Med 2000; 28: S49-56.
45. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345: 408-16.
46. Liaw PCY, Ferrell GL, Loeb M, Foley R, Weitz JI, Esmon CT. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 2001; 98: 445.
47. Hasegawa N, Kandra TG, Husari AW, Veiss S, Hart WT, Hedgpeth J, et al. The effects of recombinant human thrombomodulin on endotoxin-induced multiple-system organ failure in rats. Am J Respir Crit Care Med 1996; 153: 1831-7.
48. Maruyama I. Recombinant thrombomodulin and activated protein C in the treatment of disseminated intravascular coagulation. Thromb Haemost 1999; 82: 718-21.
49. Taoka Y, Okajima K, Uchiba M, Johno M. Neuroprotection by recombinant thrombomodulin. Thromb Haemost 2000; 83: 462-8.
50. Dreyfus M, Masterson M, David M, Rivard GE, Muller FM, Kreuz W, et al. Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital protein C deficiency. Semin Thromb Hemost 1995; 21: 371-81.
51. White B, Livingstone W, Murphy C, Hodgson A, Rafferty M, Smith OP. An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000; 96: 3719-24.
52. Rivard GE, David M, Farrell C, Schwarz HP. Treatment of purpura fulminans in meningococcemia with protein C concentrate. J Pediatr 1995; 126: 646-52.
53. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.